FDA-approved
Sexual & reproductive
Histrelin
Evidence
FDA approved
Class
GnRH agonist
KEY TAKEAWAY
Histrelin is a synthetic GnRH agonist delivered as a small implant. It is sold as Supprelin LA and Vantas. The FDA has approved histrelin implants for central precocious puberty (Supprelin LA) and for advanced prostate cancer (Vantas).
Written by the Veylo editorial team · Updated
November 2026
What it is
GnRH agonist
Approved for
Central precocious puberty in children and advanced prostate cancer
Key fact
The FDA has approved histrelin implants for central precocious puberty (Supprelin LA) and for advanced prostate cancer (Vantas).
Route
Implant placed under the skin of the upper arm
Evidence strength
FDA approved
Histrelin is a synthetic GnRH agonist delivered as a small implant. It is sold as Supprelin LA and Vantas.
Continuous exposure desensitizes GnRH receptors and lowers sex hormone production.
The FDA has approved histrelin implants for central precocious puberty (Supprelin LA) and for advanced prostate cancer (Vantas).
Central precocious puberty in children and advanced prostate cancer.
Implant-site reactions are common. In children, signs of puberty can briefly worsen at the start of treatment.
U.S. FDA prescribing information for Histrelin. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.